Miller Fisher−Guillain−Barré overlap syndrome during the Zika Virus outbreak

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Dec 30, 2017
DOI: https://doi.org/10.22551/2017.17.0404.10115
Wilma González–Barreto Gloria M. Rodríguez–Vega Patricia De Jesús–Umpierre José R. Rodríguez–Vázquez

Abstract

Miller Fisher is a variant of Guillain–Barré syndrome, presented mainly with ataxia, areflexia and ophthalmoplegia. After the 2016 Zika virus (ZIKV) outbreak, an association between Guillain–Barré syndrome and ZIKV was established. ZIKV is a mosquito–borne–flavivirus, considered a mild disease with symptoms including fever, rash, conjunctivitis, and arthralgia. Most of cases with ZIKV infection are asymptomatic, however in neurologic complications including Guillain–Barré syndrome, symptoms could evolve leading to fatalities. A case of Miller Fisher–Guillain–Barré overlap syndrome during the 2016 ZIKV outbreak is presented.

##plugins.themes.bootstrap3.article.details##

Keywords

Miller Fisher–Guillain–Barré overlap syndrome, Miller Fisher variant, Guillain–Barré syndrome, Zika Virus infection, Puerto Rico

References
1. Dirlikov E, Ryff KR, Torres–Aponte J, et al. Update: Ongoing Zika virus transmission–Puerto Rico. MMWR Morb Mortal Wkly Rep 2016; 65(17):451–55.
2. Sharp TM, Muñoz–Jordán J, Perez–Padilla J, et al. Zika virus associated with severe thrombocytopenia. Clin Infect Dis 2016; 63(9):1198–1201.
3. Cao–Lormeau V, Blake A, Mons S, et al. Guillain–Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. Lancet 2016; 387(10027):1531-1539.
4. Hennessey M, Fischer M, Staples E. Zika virus spreads to new areas – region of the Americas, May 2015–January 2016. MMWR Morb Mortal Wkly Rep 2016; 65(3):55–58.
5. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366(24):2294-2304.
6. Yepishin IV, Allison RZ, Kaminskas DA, Zagorski NM, Liow KK. Miller Fisher syndrome: A case report highlighting heterogeneity of clinical features and focused differential diagnosis. Hawaii J Med Public Health 2016; 75(7):196-199.
7. Dirlikov E, Major CE, Mayshack M, et al. Guillain-Barré syndrome during ongoing Zika Virus transmission – Puerto Rico, January 1–July 31, 2016. MMWR Morb Mortal Wkly Rep 2016; 65(34):910-914.
8. Dirlikov E, Kniss K, Major C, et al. Guillain–Barré syndrome and healthcare needs during Zika virus transmission, Puerto Rico, 2016. Emerg Infect Dis 2017; 23(1):134-136.
9. Salinas JL, Major CG, Pastula DM, et al. Incidence and clinical characteristics of Guillain–Barré syndrome before the introduction of Zika virus in Puerto Rico. J Neurol Sci 2017. doi: 10.1016/j.jns.2017.04.006
10. dos Santos T, Rodriguez A, Almiron M, et al. Zika virus and Guillain-Barré syndrome–Case series from seven countries. N Engl J Med 2016; 375:1598-1601.
11. Pan American Health Organization. Guidelines for surveillance of Zika virus disease and its complications. Washington, D.C.: PAHO, 2016. [http://iris.paho.org/xmlui/bitstream/handle/123456789/28405/9789275118948_eng.pdf?sequ-ence=1&isAllowed=y available at 26.12.2017]
12. Adams L, Bello–Pagán M, Lozier M, et al. Update: Ongoing Zika virus transmission – Puerto Rico. MMWR Morb Mortal Wkly Rep 2016; 65(30):774–779.
13. Rabe IB, Staples JE, Villanueva J, et al. Interim guidance for interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep 2016; 65.
14. Guidance for U.S. Laboratory testing for Zika virus infection: Implications for health care providers. MMWR Morb Mortal Wkly Rep 2016; 65(46):1304.
15. Sever M, Aksay E, Gulec F. The diagnosis is made only with suspicion: Miller Fisher syndrome. Hong Kong Jour Emerg Med 2011; 18(6):428-431.
16. Wakerley BR, Yuki N. Mimics and chamaleons in Guillain–Barré and Miller Fisher syndromes. Pract Neurol 2015; 15(2):90-99.
17. Sejvar JJ, Hohl KS, Gidudu J, et al. Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:599–612.
18. Farmakidis C, Inan S, Milstein M, Herskovitz S. Headache and pain in Guillain–Barré syndrome. Curr Pain Headache Rep 2015; 19:40.
19. Pirotta T, Chircop C, Vella N. Is headache a common symptom in Miller Fisher syndrome? – two case reports. J Autoimmun Res 2016; 3(1):1011.
20. Friedman DI, Potts E. Headache associated with Miller Fisher syndrome. Headache 2007; 1347–1348.
21. Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglubin therapy: A review of evidence. Autoimmun Rev 2015; 15(2016):71–81.
22. Odaka M, Yuki N, Hirata K. Anti–GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70:50–55.
How to Cite
González–Barreto, W., Rodríguez–Vega, G. M., De Jesús–Umpierre, P., & Rodríguez–Vázquez, J. R. (2017). Miller Fisher−Guillain−Barré overlap syndrome during the Zika Virus outbreak. Archive of Clinical Cases, 4(4), Arch Clin Cases 2017; 4(4):199-203. https://doi.org/10.22551/2017.17.0404.10115
Issue
Vol. 4 No. 4 (2017)
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

González–Barreto, W., Rodríguez–Vega, G. M., De Jesús–Umpierre, P., & Rodríguez–Vázquez, J. R. (2017). Miller Fisher−Guillain−Barré overlap syndrome during the Zika Virus outbreak. Archive of Clinical Cases, 4(4), Arch Clin Cases 2017; 4(4):199-203. https://doi.org/10.22551/2017.17.0404.10115